FDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.
Experts explain why more plans are getting involved in private exchanges, and share recommendations for what to do about it.
Industry experts weigh the options between a traditional pharmacy benefits manager and a pharmacy benefits administrator.
Americans are spending more time evaluating their insurance options, and more Americans are considering different sources.
The high cost of these medications could overwhelm patients and plans, according to one expert.
The Academy of Managed Care Pharmacy (AMCP) is opposing Ohio House Bill 248, because it believes the bill would mandate coverage of abuse-deterrent opioid analgesic drug products “without regard to the balance between the unique and varied needs of individual patients.”
IIn a new long-term study, nintedanib (Ofev) improved forced vital capacity (FVC) and other idiopathic pulmonary fibrosis (IPF) symptoms. The findings were presented recently at the American Thoracic Society (ATS) 2015 International Conference in Denver.
Pharmacies should be wary of potential drug name changes that could occur if FDA finalizes its new draft guidance on biosimilar naming, which proposes proper names for biosimilars.
Decades of research shows that brainstorming doesn’t work when attempting to solve difficult problems. Here's what healthcare leaders should do instead.
The inability to coordinate care for these seniors leads to more health problems, and higher costs.
A health kiosk-decision support system may be a novel and important approach to improve provider prescription patterns.
The impact of the reemergence of untreatable infections on our healthcare costs could be prohibitive. Find out what's being done about it.
Among the most significant changes today is the transformation of patients to health consumers. Here's how plans and providers should adapt.
Program aims to prevent drug diversion
FDA has approved empagliflozin and metformin hydrochloride (Synjardy, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company) tablets for the treatment of adults with type 2 diabetes.
FDA has expanded approval of eltrombopag (Promacta, Novartis) to treat low blood platelet count in pediatric patients with chronic immune thrombocytopenic purpura.
Fortune describes the 5 fastest-growing US pharmaceutical manufacturers.
The drop in the number of uninsured may seem like a good thing, but managed care executives need to be on guard in three areas.
4 things formulary managers can do to save lives and resources.
Historically, behavioral health data hasn’t been part of the clinical medical record, yet this information can help providers more accurately predict health behaviors.
Time to answer might seem like a small feature on a remote island of healthcare data systems, but it's a linchpin of software usability for daily patient encounters.
First injectable cholesterol drugs approved
Spending on healthcare can be good, but in the case of diabetes, more spending likely means worsening outcomes.
FDA’s approval of the first 3D-printed pill – Spritam to control epileptic seizures – will have a major impact on the medical and pharmaceutical community as a whole.
FDA’s long-awaited approval of Addyi (flibanserin) to treat hypoactive sexual desire disorder in premenopausal women, is significant for the prescribing community.
Jardiance is the first diabetes drug that has also been shown to lower strokes, heart attacks and cardiovascular deaths, according to a new study.
It’s time for organizations to expand the way they think about and employ PAs by looking at how the profession can impact areas where there are real needs.
Cindy Cooke, president of the American Association of Nurse Practitioners, shares 10 ways nurse practitioners reduce healthcare costs while improving quality.
FDA has approved sNDA for new formulation of fentanyl buccal soluble film (Onsolis, BioDelivery Sciences International) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.
While FDA is proposing that bevacizumab (Avastin) for macular degeneration be used within 5 days of re-packaging to avoid development of endophthalmitis in patients, that precaution may not be necessary, according to a new study.
